Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: Retrospective survey of open-label treatment

被引:36
作者
Rosenfeld, WE
Sachdeo, RC
Faught, RE
Privitera, M
机构
[1] ST LUKES HOSP,COMPREHENS EPILEPSY CARE CTR CHILDREN & ADULTS,ST LOUIS,MO
[2] ROBERT WOOD JOHNSON UNIV HOSP,COMPREHENS EPILEPSY PROGRAM NEW JERSEY,NEW BRUNSWICK,NJ
[3] UNIV ALABAMA,MED CTR,DEPT NEUROL,BIRMINGHAM,AL 35294
[4] UNIV CINCINNATI,MED CTR,DEPT NEUROL,CINCINNATI,OH 45267
关键词
anticonvulsants; topiramate; drug toxicity; drug therapy;
D O I
10.1111/j.1528-1157.1997.tb04516.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Because initial studies of new antiepileptic drugs (AEDs) are add-on trials in refractory patient populations, their effectiveness as monotherapy is usually not apparent until relatively later in their development programs. The novel AED topiramate (TPM) has been found efficacious as adjunctive therapy in controlled, randomized trials in adults with partial onset seizures. We report a retrospective analysis of TPM as AED monotherapy in 214 patients from five centers who received TPM in investigational trials. Of this total, 136 (64%) were still receiving TPM at the time of the analysis, with a mean treatment duration of 2.5 years. One-third of the patients have been successfully converted to TPM monotherapy, and 62% of those converted have been seizure-free for at least 3 months. The results of this analysis suggest that TPM may prove to be a valuable new AED for both monotherapy and add-on therapy in partial onset epilepsy.
引用
收藏
页码:S34 / S36
页数:3
相关论文
共 8 条
[1]   Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages [J].
Faught, E ;
Wilder, BJ ;
Ramsay, RE ;
Reife, RA ;
Kramer, LD ;
Pledger, GW ;
Karim, RM ;
Barr, A ;
Fischer, J ;
Bergen, D ;
Boor, D ;
Browne, T ;
Davenport, J ;
Dichter, M ;
Drake, M ;
Kuzniecky, R ;
Mamdani, M ;
McCutchen, C ;
Naritoku, D ;
Potolicchio, S ;
Ramani, V ;
Ramsay, R ;
Shinnar, S ;
So, E ;
Wilder, B .
NEUROLOGY, 1996, 46 (06) :1684-1690
[2]  
OXLEY J, 1983, CHRONIC TOXICITY ANT
[3]   CLINICAL-TRIALS OF INVESTIGATIONAL ANTIEPILEPTIC DRUGS - MONOTHERAPY DESIGNS [J].
PLEDGER, GW ;
KRAMER, LD .
EPILEPSIA, 1991, 32 (05) :716-721
[4]   EVALUATION OF ANTIEPILEPTIC DRUG EFFICACY - A REVIEW OF CLINICAL-TRIAL DESIGN [J].
PLEDGER, GW ;
SCHMIDT, D .
DRUGS, 1994, 48 (04) :498-509
[5]   Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages [J].
Privitera, M ;
Fincham, R ;
Penry, J ;
Reife, R ;
Kramer, L ;
Pledger, G ;
Karim, R ;
Bourgeois, B ;
Carter, G ;
Ferrendelli, J ;
Fincham, R ;
Fromm, G ;
Gallagher, B ;
Harner, R ;
Holmes, M ;
Leroy, R ;
Penry, J ;
Privitera, M ;
Rosenfeld, W ;
Rowan, A ;
Sackellares, JC ;
Smith, D ;
Willmore, L ;
Wyler, A .
NEUROLOGY, 1996, 46 (06) :1678-1683
[6]   MONOTHERAPY OR POLYTHERAPY FOR EPILEPSY [J].
REYNOLDS, EH ;
SHORVON, SD .
EPILEPSIA, 1981, 22 (01) :1-10
[7]  
SACHDEO SK, 1995, EPILEPSIAS4, V36, pS33
[8]  
SCHMIDT D, 1982, ADVERSE EFFECTS ANTI